Effects of a D-xylose preload with or without sitagliptin on gastric emptying, glucagon-like peptide-1, and postprandial glycemia in type 2 diabetes

Diabetes Care

Volumn 36, Issue 7, 2013, Pages 1913-1918

  Wu, Tongzhi ^a   Bound, Michelle J ^a   Zhao, Beiyi R ^a   Standfield, Scott D ^a   Bellon, Max ^b   Jones, Karen L ^a   Horowitz, Michael ^a   Rayner, Christopher K ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; OCTANOIC ACID C 13; PLACEBO; SITAGLIPTIN; SUCRALOSE; XYLOSE;

AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; FEMALE; FLUID INTAKE; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MACRONUTRIENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; POSTPRANDIAL STATE; POTATO; RANDOMIZED CONTROLLED TRIAL; STOMACH EMPTYING; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTRIC EMPTYING; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PYRAZINES; RADIOIMMUNOASSAY; TRIAZOLES; XYLOSE;

EID: 84886050803     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2294     Document Type: Article

References (40)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-1596
2. El-Kebbi IM, Ziemer DC, Cook CB, Gallina DL, Barnes CS, Phillips LS. Utility of casual postprandial glucose levels in type 2 diabetes management. Diabetes Care 2004;27:335-339
3. Chaikomin R, Rayner CK, Jones KL, Horowitz M. Upper gastrointestinal function and glycemic control in diabetes mellitus. World J Gastroenterol 2006;12: 5611-5621
4. Horowitz M, Edelbroek MA, Wishart JM, Straathof JW. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 1993;36:857-862
5. Jones KL,Horowitz M, Carney BI,Wishart JM, Guha S, Green L. Gastric emptying in early noninsulin-dependent diabetes mellitus. J Nucl Med 1996;37:1643-1648
6. Holst JJ, Vilsböll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009;297:127-136
7. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-52
8. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R,Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91:301-307
9. Deane AM, Nguyen NQ, Stevens JE, et al. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 2010;95:215-221
10. Schirra J, Göke B. The physiological role of GLP-1 in human: incretin, ileal brake or more? Regul Pept 2005;128:109-115
11. De Silva A, SalemV, Long CJ, et al. The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans. Cell Metab 2011;14:700-706
12. Gentilcore D, Chaikomin R, Jones KL, et al. Effects of fat on gastric emptying of and the glycemic, insulin, and incretin responses to a carbohydrate meal in type 2 diabetes. J Clin Endocrinol Metab 2006; 91:2062-2067
13. Ma J, Stevens JE, Cukier K, et al. Effects of a protein preload on gastric emptying, glycemia, and gut hormones after a carbohydrate meal in diet-controlled type 2 diabetes. Diabetes Care 2009;32:1600-1602
14. Wu T, Zhao BR, Bound MJ, et al. Effects of different sweet preloads on incretin hormone secretion, gastric emptying, and ostprandial glycemia in healthy humans. Am J Clin Nutr 2012;95:78-83
15. Fordtran JS, Soergel KH, Ingelfinger FJ. Intestinal absorption of D-xylose in man. N Engl J Med 1962;267:274-279
16. Craig RM, Ehrenpreis ED. D-xylose testing. J Clin Gastroenterol 1999;29:143-150
17. Vanis L, Hausken T, Gentilcore D, et al. Comparative effects of glucose and xylose on blood pressure, gastric emptying and incretin hormones in healthy older subjects. Br J Nutr 2011;105:1644-1651
18. Qualmann C, Nauck MA, Holst JJ,Orskov C, Creutzfeldt W. Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose fromthe upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol 1995;30:892-896
19. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368:1696-1705
20. Ahrén B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab 2007;21:517-533
21. Ma J, Bellon M, Wishart JM, et al. Effect of the artificial sweetener, sucralose, on gastric emptying and incretin hormone release in healthy subjects. Am J Physiol Gastrointest Liver Physiol 2009;296:G735-G739
22. Ma J, Chang J, Checklin HL, et al. Effect of the artificial sweetener, sucralose, on small intestinal glucose absorption in healthy human subjects. Br J Nutr 2010; 104:803-806
23. Ghoos YF, Maes BD, Geypens BJ, et al. Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology 1993;104:1640-1647
24. Chew CG, Bartholomeusz FD, Bellon M, Chatterton BE. Simultaneous 13C/14C dual isotope breath test measurement of gastric emptying of solid and liquid in normal subjects and patients: comparison with scintigraphy. Nucl Med Rev Cent East Eur 2003;6:29-33
25. Jones HF, Burt E, Dowling K, Davidson G, Brooks DA, Butler N. Effect of age on fructose malabsorption in children presenting with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 2011;52: 581-584
26. Wolever TM. Effect of blood sampling schedule and method of calculating the area under the curve on validity and precision of glycaemic index values. Br J Nutr 2004;91:295-301
27. Standl E, Schnell O, Ceriello A. Postprandial hyperglycemia and glycemic variability: should we care? Diabetes Care 2011;34(Suppl. 2):S120-S127
28. Barker GR, Cochrane GM, Corbett GA, Hunt JN, Roberts SK. Actions of glucose and potassiumchloride on osmoreceptors slowing gastric emptying. J Physiol 1974; 237:183-186
29. Wu T, Rayner CK, Jones K, Horowitz M. Dietary effects on incretin hormone secretion. Vitam Horm 2010;84:81-110
30. Naula CM, Logan FJ, Wong PE, Barrett MP, Burchmore RJ. A glucose transporter can mediate ribose uptake: definition of residues that confer substrate specificity in a sugar transporter. J Biol Chem 2010; 285:29721-29728
31. Chaikomin R, Doran S, Jones KL, et al. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects. Am J Physiol Endocrinol Metab 2005;289: E504-E507
32. Pilichiewicz AN, Chaikomin R, Brennan IM, et al. Load-dependent effects of duodenal glucose on glycemia, gastrointestinalhormones, antropyloroduodenal motility, and energy intake in healthy men. Am J Physiol EndocrinolMetab 2007;293:E743-E753
33. Stevens JE, Horowitz M, Deacon CF, Nauck M, Rayner CK, Jones KL. The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study. Aliment Pharmacol Ther 2012;36: 379-390
34. Schvarcz E, Palmér M, Aman J, Horowitz M, Stridsberg M, Berne C. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulindependent diabetes mellitus. Gastroenterology 1997;113:60-66
35. Witte AB, Grybäck P, Holst JJ, et al. Differential effect of PYY1-36 and PYY3-36 on gastric emptying in man. Regul Pept 2009;158:57-62
36. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287:E199-E206
37. Prigeon RL, Quddusi S, Paty B, D'Alessio DA. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol Endocrinol Metab 2003;285: E701-E707
38. Muscelli E, Casolaro A, Gastaldelli A, et al. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 2012; 97:2818-2826
39. Edgerton DS, Johnson KM, Neal DW, et al. Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog. Diabetes 2009;58:243-249
40. Migoya EM, Bergeron R, Miller JL, et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010;88:801-808